Esperion Therapeutics | ESPR - Net Income


Esperion Therapeutics reported $-29.52M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Alterity Therapeutics Limited AUD -5.77M 2.26M Jun/2023
Amarin USD -7.74M 6.4M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Cipla INR 6.76B 6.75B Dec/2025
CSL USD 497.5M 1.51B Jun/2025
Cytokinetics USD -306.18M 171.81M Sep/2025
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Geron USD -18.43M 2.05M Sep/2025
Grifols EUR 148.4M 15.76M Sep/2025
Halozyme Therapeutics USD 175.22M 10.06M Sep/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Moderna USD -200M 625M Sep/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Pfizer USD -1.65B 5.19B Dec/2025
PTC Therapeutics USD 15.9M 80.75M Sep/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
United Therapeutics USD 338.7M 29.2M Sep/2025
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024